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In vitro anticancer activity
Crystal structureThe organotin(IV) compoundsMe2SnCl2(dbtp)(1), Me2SnCl2(dbtp)2 (2), Et2SnCl2(dbtp) (3), Et2SnCl2(dbtp)2
(4), Et2SnCl2(dptp) (5),
nBu2SnCl2(dbtp)2 (6),
nBu2SnCl2(dptp) (7), Ph2SnCl2(dbtp) (8), Ph2SnCl2(EtOH)2
(dptp)2 (9), where dbtp = 5,7-di-tert-butyl-1,2,4-triazolo[1,5-a]pyrimidine and dptp = 5,7-diphenyl-
1,2,4-triazolo [1,5-a]pyrimidine, have been tested by MTT for their cytotoxic activity on three tumor cell
lines, HepG2 (humanhepatocellular carcinoma), HeLa (human cervix adenocarcinoma) andMCF-7 (human
breast cancer). Except for 1 and 2, which were ineffective, all compounds signiﬁcantly showed a dose-
dependent anti-proliferative effect against the three cell lines. By calculated IC50 values, the cytotoxicity
of the complexes followed the order nBu > Ph > Et > Me for all the selected tumor cells. The cell death of
HepG2, induced by organotin(IV) compounds 6–9, was considered to be apoptotic by measuring the expo-
sure of phosphatidylserine to the outer membrane and observing the typical apoptotic morphological
change by acridine orange/ethidium bromide staining. Flow cytometric analysis of propidium iodide-
stained cells also demonstrated that organotin(IV) complexes caused apoptosis of HepG2 cells through cell
arrest at G0–G1 phase. The crystal structure of 7, investigated by X-ray diffraction study, exhibited a
distorted trigonal bipyramidal geometry with N, Cl as axial atoms and Cl and butyl groups in the equatorial
plane. The triazolopyrimidine unit coordinates to the Sn atom through N(3) in a monodentate mode. Two
conformational isomers (molecule A and B in the crystallographic independent unit) are co-crystallized in
the solid state, a phenomenon that has been observed only occasionally. Conformational mobility of the
cytotoxic complex 7 can sum up to the ligands ability to form H-bonds and p  p stacking, facilitating its
intracellular uptake.
 2014 Elsevier B.V. All rights reserved.1. Introduction
The chemistry of organotins has attracted much attention in
recent years, owing to potential biological and industrial applica-
tions. The organotin(IV) compounds have shown a wide variety of
biological activities: bactericidal, fungicidal, biocidal and pesticidal
[1]. In addition, many organotin(IV) compounds have been tested
for their in vitro activity against a large variety of tumor cell lines
and have been found to be as effective, or better, than traditionalheavy metal anticancer drugs such as cisplatin [2]. In general, the
biochemical activity of organotin(IV) complexes is inﬂuenced
greatly by the structure of the molecule and the coordination num-
ber of the tin atoms [3]; it is well known that the biological activity
of organotin(IV) complexes is related to the number of Sn–C bonds
and the type of groups in the organotin moiety. The organotin(IV)
compounds with triazolopyrimidine ligands have not been investi-
gated to a large extent. Considering that organotin(IV) compounds
are promising also in cancer therapy, we have decided to study a
class of R2SnCl2(L)2 and R2SnCl2(L) type complexes (R = Me, Et,
nBu, Ph and L = dbtp or dptp).
Triazolopyrimidines [4] represent an interesting class of hetero-
cycles due to the number and the arrangement of the nitrogen
atoms in the aromatic cycle as well as the nature of the ring substit-
uents. Some transitionmetal complexes (e.g. Ag(I), Cu(II), Pt(II), and
Pd(II)) with triazolopyrimidines signiﬁcantly inhibit the in vitro cell
Scheme 1. The structure of ligands dbtp and dptp.
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studies (in vitro) of cis-dichloro platinum(II) compounds with
triazolopyrimidine ligands dbtp and dptp [5] indicate a moderate
antiproliferative activity against the cells of rectal, breast and blad-
der cancer. Cytotoxicity parameters pointed out that the antitumor
activity of the investigated platinum(II) compounds containing
1,2,4-triazolo[1,5-a]pyrimidines depends directly on the geometry
around platinum(II) and the kinds of ligands involved. When the
antitumor activity of the triazolopirymidine complexes is related
to substitutions in the pyrimidine ring, their electronic and stereo-
chemical impact is unequivocal. Previous studies on cis-dichloro
platinum(II) compounds with 5,7-disubstituted-1,2,4-triazolo
[1,5-a]pyrimidines suggested that the presence of a bulky ligand
(tert-butyl or a phenyl group in the triazolopyrimidine ring) might
be a major factor in the antitumor activity of the platinum(II) com-
pounds [6]. Reported X-ray structures conﬁrmed the presence of
monodentate triazolopyrimidines in many coordination com-
pounds; in each case the heterocyclic ligand binds via N(3), in
mononuclear Pt(II) [7], Pd(II) [8] and Ru(III) [9] coordination com-
pounds. A special feature of these complexes is that theyweremod-
eled on the active square-planar Pt(II) complexes which have cis
halogen groups and yet the mode of action for the formation of
metal-based cross-links is reported to follow a different route for
organotin adducts [10]. Among the diorganotin(IV) compounds,
di-n-butyltin(IV) derivatives have received more attention due to
their antitumor activity stronger than that of dimethyltin(IV) or
diethyltin(IV) analogs. However, their antitumor mechanisms
of action are still not elucidated [11]. Investigations on ‘induction
of apoptosis’ by metal-based drugs have become popular with
cisplatin and ruthenium compounds, suggesting that apoptosis is
a possible key event in mediating the in vitro antitumor activity of
these compounds. Inspired by the apoptosis mechanism of these
metal-based antitumor complexes, we decided to check if the
in vitro antitumor activity of organotin(IV) complexes could be
related to apoptosis by cellular biochemical studies.
Recently, we described complexes of diorganotin(IV) dichlo-
rides with the heterocyclic ligands [1,2,4]triazolo-[1,5-a]pyrimi-
dine (tp), 5,7-dimethyl-[1,2,4]triazolo-[1,5-a]pyrimidine (dmtp)
[12], 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp) and
5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp) [13] that
exhibit antibacterial activity against a group of reference pathogen
micro-organisms, thus showing antibacterial activities against a
group of reference pathogen micro-organisms, which shows their
inhibitory effect. In vitro antimicrobial tests showed that
nBu2SnCl2(dmtp) [12] has interesting properties as anti Gram-
positive and antibioﬁlm agent.
The present study was aimed to widen the knowledge about
bio-activity of organotin(IV) compounds. We here investigate
inhibitory effects of complexes with triazolopyrimidine on the
growth of a number of human malignant cell lines and assess
the inﬂuence of the substituents (tert-butyl or phenyl) attached
to the heterocyclic ring and the type of alkyl or phenyl groups
attached to the tin atom, on their biological activity. The
formerly characterized organotin(IV) compounds [13] assayed
in this study were: Me2SnCl2(dbtp)(1), Me2SnCl2(dbtp)2 (2),
Et2SnCl2(dbtp) (3), Et2SnCl2(dbtp)2 (4), Et2SnCl2(dptp) (5),
nBu2SnCl2(dbtp)2 (6), nBu2SnCl2(dptp) (7), Ph2SnCl2(dbtp) (8),
Ph2SnCl2(EtOH)2(dptp)2 (9). All complexes were evaluated for
their in vitro anti-proliferative activity against three human can-
cer cell lines: HepG2 (human hepatocellular carcinoma), HeLa
(human cervix adenocarcinoma) and MCF-7 (human breast can-
cer). The apoptosis of HepG2 cells induced by the most active
complexes was also investigated using ﬂow cytometry as
well as ﬂuorescence microscopy. Moreover, crystal structure of
nBu2SnCl2(dptp), 7, whose spectroscopical parameters have been
previously reported [13], is also discussed.2. Experimental
2.1. Diorganotin(IV) compounds, R2SnCl2(L)2 and R2SnCl2(L)
The synthesis and characterization of the compounds R2SnCl2
(L)2 and R2SnCl2(L) (1–9) where R = Me, Et, nBu and Ph, while
L = 5,7-di-tert-butyl-1,2,4-triazolo[1,5-a]pyrimidine (dbtp) and/or
5,7-diphenyl-1,2,4-triazolo[1,5-a]pyrimidine (dptp) (Scheme 1)
were reported earlier [13] and will not be discussed here. Scheme 2
shows the proposed structures for R2SnL2 and R2SnL complexes.2.2. X-ray crystallography of nBu2SnCl2(dptp) (7)
Crystals of 7, suitable for the X-ray diffraction studies, were
grown on slow evaporation of a methanol solution of the complex
(Fig. 1). Preliminary examination and data collection were carried
out at ambient temperature on a Sapphire CCD detector (Oxford
Diffraction Ltd., Agilent Technologies, USA) with Mo Ka radiation,
k = 0.71073 Å, monochromator graphite.
Data reduction was automatically performed by CrysAlisPRO
(Oxford Diffraction Ltd., UK). The cell parameters were obtained
and reﬁned using the PHICHI [14] and DIRAX [15] programs,
respectively, catching reﬂections with random orientation in hkl
planes. Intensities were corrected by Lorentz polarization and
absorption with the SADABS [16] program. The XPREP [17] program
was used for analysis of the data reduction and revealed an ortho-
rhombic P group. The structure was solved by direct methods using
the SHELXS-97 [18] program. SHELX-97 was used for structure solution
and reﬁnement based on F2. The asymmetric unit contains two
crystallographically independent molecules, A and B, two conform-
ers differing in both the butyl groups and the phenyl ring orienta-
tions Fig. 2. The butyl moieties, particularly those of molecule B,
are characterized by large thermal vibrations; however, no satis-
factory alternative model for the disordered atoms could be reﬁned
despite repeated attempts. The two independent molecules were
separately reﬁned by blocked-matrix least squares methods, giving
to each correspondent atom the same crystallographic numbering
with A or B labels. Non-hydrogen atoms were reﬁned isotropically,
apart from Sn and Cl atoms. Hydrogen atoms bound to carbon
atoms were added in calculated positions. Aromatic carbon atoms
were reﬁned with Uiso(H) = 1.2 Ueq C sp2 and methyl carbon s with
Uiso(H) = 1.5 Ueq C sp3. Final R indexes for 249 parameters reﬁned
R1 = 0.0582 [(I) > 2r(I)] and 0.1807 for all 9256 data,
wR2 = 0.11146 [(I) > 2r(I)], GooF S = 0.910 for all data. Flack x
parameter = 0.04 with e.s.d = 0.05.
Crystal data and details of measurements are reported in
Table 1. Molecular graphics were prepared using ORTEP-3 for
Windows [19].
Scheme 2. Proposed structures [Ref. 13] for R2SnL and R2SnL2 complexes: (a) R = Me, Et, nBu, Ph; L = dbtp and/or dptp (compounds 1,3,5,7,8). (b) R = Ph; L = dptp (compound
9). (c) R = Me, Et, nBu; L = dbtp (compounds 2,4,6).
Fig. 1. Ortep drawing (30% probability) of molecule A [nBu2SnCl2(dptp) (7)]
showing the crystallographic numbering.
Fig. 2. Stick representation of molecules A and B [nBu2SnCl2(dptp) (7)] showing the
different conformations of the butyl chains.
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The tested complexeswere dissolved in ethanol and then diluted
in culture medium so that the effective alcohol concentration did
not exceed 0.2%. HepG2, HeLa and MCF-7 cell lines and human
hepatic Chang liver cells were purchased from American Type Cul-
ture Collection, Rockville, MD, USA. All of themwere grown in RPMI
medium supplemented with L-glutamine (2 mM), 10% fetal bovine
serum (FBS), penicillin (100 U/mL), streptomycin (100 lg/mL) and
gentamicin (5 lg/mL). HepG2 culture medium also contained
sodium pyruvate (1.0 mM). Cells were maintained in log phase by
seeding twice a week at a density of 3  108 cells/L in humidiﬁed
5% CO2 atmosphere, at 37 C. In all experiments, cells were made
quiescent through overnight incubation before the treatment with
the compounds or vehicle alone (control cells). No differences werefound between cells treatedwith ethanol 0.2% and untreated cells in
terms of cell number and viability.
Cytotoxic activity of the organotin(IV) complexes against three
human tumor cell lines HepG2, MCF-7, HeLa and human hepatic
Chang liver cells was determined by the MTT colorimetric assay
based on the reduction of 3-(4,5-dimethyl-2-thiazolyl)bromide-
2,5-diphenyl-2H-tetrazolium (MTT) [20] to purple formazan by
mitochondrial dehydrogenases of living cells. This method is
commonly used to illustrate inhibition of cellular proliferation.
Monolayer cultures were treated for 24 h with various concentra-
tions (0.1–50 lM) of the drugs and cisplatin was used as the posi-
tive control. Brieﬂy, all cell lines cells were seeded at 2  104 cells/
well in 96-well plates containing 200 lL RPMI. After an overnight
incubation, cells were washed with fresh medium and incubated
with the compounds in RPMI. After a 24 h incubation, cells were
washed, and 50 lL FBS-free medium containing 5 mg/mL MTT
were added. The medium was discarded after a 2 h incubation at
37 C by centrifugation, and formazan blue formed in the cells
was dissolved in dimethyl sulfoxide (DMSO). The absorbance, mea-
sured at 570 nm in a microplate reader (Bio-RAD, Hercules, CA), of
MTT-formazan of control cells was taken as 100% of viability.
IC50 value for each assessed compound was calculated by plot-
ting the percentage viability versus concentration on a logarithmic
graph and reading off the concentration at which 50% of cells
remained viable relative to the control. Each experiment was
repeated at least three times in triplicate to obtain the mean
values.
2.4. Measurement of phosphatidylserine exposure
The externalization of phosphatidylserine (PS) to the cell surface
was detected by ﬂow cytometry by double staining with Annexin
V/propidium iodide (PI). HepG2 cells were seeded in triplicate in
24-wells culture plates at a density of 5.0  104 cells/cm2. After an
overnight incubation, the cells were washed with fresh medium
and incubated with the compounds in RPMI. After 24 h, cells were
harvested by trypsinization and adjusted at 1.0  106 cells/mL with
combining buffer. One hundred microliters of cell suspended
solution was added to a new tube, and incubated with Annexin V
and PI solution according to the manufacturer’s instructions
(eBioscience, San Diego, CA) at room temperature in the dark for
15 min. Then samples of at least 1.0  104 cells were subjected to
ﬂuorescence-activated cell sorting (FACS) analysis by Epics XL™
ﬂow cytometer using Expo32 software (Beckman Coulter, Fullerton,
CA), using appropriate 2-bidimensional gating method.
2.5. Acridine orange and ethidium bromide morphological ﬂuorescence
dye staining
Acridine orange (AO) stains DNA bright green, allowing visual-
ization of the nuclear chromatin pattern and stains both live and
dead cells. Ethidium bromide (EB) stains DNA orange but is
Table 1







a (Å) 28.346 (4)
b (Å) 24.707 (5)
c (Å) 7.531 (6)
V (Å3) 5274.30
Z 8
Density (Mg m3) 1.451
Crystal size (mm) 0.20  0.20  0.35
h Range for data collection () 2.5–25
Index range 33 6 h 6 33, 29 6 k 6 29,
8 6 l 6 8
Reﬂections collected 9256
Data/restraints/parameters 9256/2/248
Goodness-of-ﬁt (GOF) on F2 0.91
Final R indices [I > 2r(I)] R1 = 0.0582, wR2 = 0.1146
[R = 0.1807 for all 9256 data]





Selected bond distances (Å) and angles () E.s.d.s are shown in parentheses.
Molecule A Molecule B
Sn–Cl(1) 2.371 (4) 2.339 (4)
Sn–Cl(2) 2.439 (4) 2.436 (4)
Sn–N(3) 2.576 (8) 2.556 (9)
Sn–C(1) 2.074 (9) 2.117 (9)
Sn–C(5) 2.081 (8) 2.031 (9)
Cl(1)–Sn–Cl(2) 94.7 (1) 94.2 (1)
C(1)–Sn–Cl(1) 104.7 (4) 107.0 (5)
C(1)–Sn–Cl(2) 96.8 (4) 101.0 (5)
C(5)–Sn–Cl(1) 109.4 (5) 113.6 (5)
C(5)–Sn–Cl(2) 97.5 (4) 97.4 (5)
N(3)–Sn–Cl(1) 82.6 (2) 81.6 (3)
N(3)–Sn–Cl(2) 177.4 (3) 175.8 (3)
N(3)–Sn–C(1) 83.5 (4) 80.9 (5)
N(3)–Sn–C(5) 83.8 (5) 83.8 (5)
C(1)–Sn–C(5) 141.5 (6) 133.6 (4)
Geometry of C–H  Cl interaction.
C(16)A–H(16)A  Cl(1)B H  Cl distance 2.91(1) Å, C–H  Cl angle 170.8(6).
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tion of populations of viable non-apoptotic, viable (early) apopto-
tic, nonviable (late) apoptotic, and necrotic cells. Live cells appear
uniformly green. Early apoptotic cells stain green and contain
bright green dots in the nuclei as a consequence of chromatin con-
densation and nuclear fragmentation. Late apoptotic cells incorpo-
rate EB and therefore stain orange, but, in contrast to necrotic cells,
the late apoptotic cells show condensed and often fragmented
nuclei. Necrotic cells stain orange, but have a nuclear morphology
resembling that of viable cells, with no condensed chromatin.
Brieﬂy, after HepG2 cells were treated with the organotin(IV) com-
pounds for 24 h, the medium was discarded. Cells were washed
with saline 5 mM phosphate buffer (PBS) and then incubated with
100 lL PBS containing 100 lg/mL of EB plus 100 lg/mL of AO. After
20 s, EB/AO solution was discarded and cells immediately visual-
ized by means of ﬂuorescent microscope equipped with an
automatic photomicrograph system (Leica, Wetzlar, Germany).
Multiple photos were taken at randomly-selected areas of the well
to ensure that the data obtained are representative.
2.6. Cell cycle analysis
Cell cycle stage was analyzed by ﬂow cytometry. Aliquots of
1  105 cells were harvested by centrifugation, washed with
(PBS) and incubated in the dark in a PBS solution containing
20 lg/mLPI and 200 lg/mL RNase, for 30 min, at room tempera-
ture. The samples were then immediately subjected to FACS
analysis. At least 1x104 cells were analyzed for each sample.3. Results and discussion
3.1. Crystal structure of nBu2SnCl2(dptp) (7)
The crystal structure of 7 is shown in Fig. 1 as an Ortep repre-
sentation (30% probability) together with the atomic crystal num-
bering. Signiﬁcant bond distances and angles are reported in
Table 2. In agreement with IR and Mössbauer evidences [13],
nBu2SnCl2(dptp) is a ﬁve-coordinated Sn species; X-ray diffraction
studies conﬁrm a distorted trigonal bipyramidal geometry with
N, Cl as axial atoms and Cl and butyl groups in the equatorial plane.
The triazolopyrimidine unit coordinates to the Sn atom throughN(3) in a monodentate mode, with Sn–N(3) bond distance of
2.576(8) and 2.556(8) Å for molecule A and B respectively, trans
to Cl(2), Sn–Cl(2) 2.439(4) and 2.436(4) Å for molecule A and B
respectively (Fig. 2). The present distance [2.566 Å as an average]
is well beyond the ‘‘threshold’’ for activity, according to Crowe
[21]: actually, longer Sn–N bond lengths in diorganotin(IV) com-
plexes containing an N-donor atom, particularly greater than
2.39 Å, could apparently favour binding to DNA, whereas the inac-
tive complexes had Sn–N bonds <2.39 Å. The rationale behind this
is that the ligand predissociation may be an important step in the
complex mode of action promoting the formation of a Sn-DNA
complex, at least for bidentate N ligands. Our previous structural
investigations on this class of complexes revealed that also
compound 4 shows a quite long Sn–N bond [2.603(2) Å] while no
comparison can be made for compound 9, where the N atom of
the dptp moiety is H-bonded to the O atom of the ethanol Sn
ligand, no direct Sn–N interaction being present [13].
The angles depicting coordination around the tin atom range
from 177.4(3), for N(3)–Sn–Cl(2), the trans axial ligands, to the
signiﬁcantly distorted equatorial plane where there is a clear dif-
ference in the bond angles between the two conformers (molecule
A and B in the crystallographic independent unit) due to the differ-
ent butyl groups conformation and relative orientation. Actually,
the angle C(1)–Sn–C(5) is 141.5(6) for the butyl groups of mole-
cule A and 133.6(6) for molecule B. That is, in molecule A both
the butyl groups exhibit an anti conformation with a relative cisoid
orientation of the ligands with respect to the Cl(1)–Sn–Cl(2)–N(3)
plane. C(2) and C(6) lie on the same side with respect to the above
mentioned plane, thus widening the bond angle between C(1) and
C(5). Overall, the SnC2Cl2N center displays local C2 site symmetry
and the triazolopyrimidine plane comprises also the C(20) to
C(25) phenyl ring, while C(14) to C(19) phenyl ring forms an angle
of 28.7(3)with the previous one. In molecule B, on the other hand,
one butyl ligand exhibits an anti conformation while the other one
has a gauche one, thus resulting in a local lack of symmetry, where
neither phenyl ring lies exactly on the triazolopyrimidine plane.
Taking into account bond angles, perhaps a better description of
the tin coordination for molecule B is that of a distorted square
pyramid where Cl(2) occupies the axial site, while Cl(1), N and
the C atoms deﬁne the base, according to a distorted cis-R2 trigonal
bipyramidal structure determined by Mössbauer spectroscopy
[13]. The other bond angles at the tin atom are the following:
C(1)–Sn–Cl(1) angle 105.8(4) on average, C(5)–Sn–Cl(1)
109.4(5) and 113.6(5) for molecule A and B respectively. N(3)–
Sn–C(1) is 82.2(4) av., N(3)–Sn–C(5) 83.8(5) av., Cl(1)–Sn–Cl(2)
94.4(2) av., Cl(2)–Sn–C(1) 96.8(4) and 101.0(5) for A and B and
Table 3
Calculated IC50 (lM) valuesa for anti-proliferative activity of organotin(IV) complexes
against different human cell lines.
Compound IC50 ± SD
HepG2 MCF-7 HeLa
Me2SnCl2(dbtp) (1) ndb ndb ndb
Me2SnCl2(dbtp)2 (2) ndb ndb ndb
Et2SnCl2(dbtp) (3) >50 12 ± 1.40 >50
Et2SnCl2(dbtp)2 (4) >50 15 ± 1.10 >50
Et2SnCl2(dptp) (5) 20 ± 1.50 7.5 ± 0.60 20 ± 1.50
Bu2SnCl2(dbtp)2 (6) 1.0 ± 0.11 0.3 ± 0.02 1.2 ± 0.09
Bu2SnCl2(dptp) (7) 0.6 ± 0.03 0.7 ± 0.05 1.6 ± 0.08
Ph2SnCl2(dbtp) (8) 4.0 ± 0.30 4.8 ± 0.05 7.0 ± 0.40
Ph2SnCl2(EtOH)2(dptp)2 (9) 3.0 ± 0.25 3.8 ± 0.40 7.5 ± 0.50
Cisplatin 65 ± 2 10 ± 1 17.5 ± 1.0
a IC50 value for each assessed compound was calculated by plotting the per-
centage viability versus concentration on a logarithmic graph. Cisplatin was
assayed as positive control. Results are the mean values ± SD (standard deviation) of
three separated experiment carried out in triplicate.
b nd-not detectable.
172 M.A. Girasolo et al. / Inorganica Chimica Acta 423 (2014) 168–176Cl(2)–Sn–C(5) 97.5(5) av. On the whole, the two conformers are
stabilized by a single intermolecular C–H  Cl interaction through
the C(16)–H(16) group belonging to an A molecule towards Cl(1)
of a B molecule, thus yielding A–B hetero-dimers; the geometry
of this interaction is reported in Table 2. Beside this H-bonding
interaction, many p–p and edge-to-face aromatic interactions con-
tribute to the three-dimensional packing of the molecules. These
latter interactions, interestingly, involve molecules belonging to
the same conformers, i.e. among A molecules on one side and
among B molecules on the other, where phenyl rings face towards
the six-membered ring in triazolopyrimidine. Thus, a selective self-
recognition between ‘‘homo’’-conformers drives the aromatic
supramolecular assembly of the compound, while the H-bondingFig. 3. Anti-proliferative effect of organotin(IV) complexes on HepG2 cells (a), MCF-7 (b)
absence (control) or in the presence of the compounds at the indicated concentrations
indicated as the percentage of viable cells with respect to untreated controls. Values arenetworks drives the ‘‘hetero’’ conformers recognition. This kind
of shape-induced chiral ordering in 3-D packing, where chiral
objects are produced from non chiral molecules, results in a very
efﬁcient enantiomeric close packing.
The presence of different conformers in the same crystal is occa-
sional [22] and undoubtedly linked to the low energy difference
among the different forms. However, it is known that even a
slightly disfavored torsional geometry may be compensated by a
better H-bonding or aromatic interaction. Molecular conformation
and hydrogen bonding (or p  p stacking interactions) can thus
inﬂuence each other and, in turn, the overall crystal packing. In
the present case, stabilization of the two conformers by the crystal
packing may be relevant for activity. The activity of the cytotoxic
complex 7 can be attributed to the ability of the ligand to form
unobstructed H-bonds and/or p  p stacking that may facilitate
an intracellular uptake of complexes [23].
In addition, it must be pointed out the dual role of the Sn centre
as a Lewis acid in order to coordinate the organic ligands and as a
template in properly positioning the ﬂexible moieties for new
metal-based antitumour drugs, playing also its own part in
inducing apoptosis. Chirality thus generated in crystal packing is
certainly a very important aspect in determining stereoselective
and stereospeciﬁc interaction with target molecules [24] while
an increased bio-activity may be hypothesized due to the multi-
faceted binding mode of conformers. Actually, due to the recent
serendipitous discovery of aspirin form II [25,26] polymorphism
in pharmaceutical chemistry has gained new impulse [27,28].3.2. Cytotoxicity assay in vitro
An investigation of cytotoxic activity in vitro of the organo-
tin(IV) complexes 1–9 against three human tumor cell lines
HepG2, MCF-7, HeLa and human hepatic Chang liver cells wasor HeLa (c) cells as assessed by MTT. Cell monolayers were incubated for 24 h in the
and cell viability was assessed by MTT test as reported in Section 2. Results are
the mean ± SD of three separate experiments carried out in triplicate.
Fig. 4. Effect of the complexes 6–9 on viability of non tumorigenic Chang liver cells.
Cell monolayers were incubated for 24 h in the absence (control) or in the presence
of the compounds at the indicated concentrations and cell viability was assessed by
MTT test as reported in Section 2. Results are indicated as the percentage of viable
cells with respect to untreated controls. Values are the mean ± SD of three separate
experiments carried out in triplicate.
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different tin moieties (bearing methyl, ethyl, butyl or phenyl
groups), the coordination geometry and the cytotoxic activity.
The IC50 values of the complexes against the selected tumor cell
lines are listed in Table 3, and the cell viability is depicted in
Fig. 3. Except for 1 and 2, which were ineffective, all compounds
showed a signiﬁcant dose-dependent antiproliferative effect
against the three cell lines. These results are in good agreement
with our earlier report [13] on antibacterial activity of the organo-
tin(IV) complexes, the most active being Ph2SnCl2 and nBu2SnCl2
derivatives. Comparing the IC50 values, the di-n-butyltinFig. 5. Flow cytometric analysis for the quantiﬁcation by AnnexinV/PI double staining of
for 24 h in the absence (control) or in the presence of individual complexes and submi
(AnnexinV/PI); V4, cells in early apoptosis (AnnexinV+/PI); V2, cells in tardive apopto
cells in the different apoptosis phases. Representative images of three experiments withcomplexes 6 and 7 appeared most active against all the selected
tumor cell lines, followed by diphenyltin complexes 8 and 9. Inter-
estingly, complex 7 showed higher cytotoxic activity than 6 against
HepG2 cells, but lower cytotoxicity than 6, towards MCF-7 and
HeLa cells (IC50 values signiﬁcantly different with P < 0.005,
Student’s t test). These results suggest that different complexes
display different cytotoxic effects on different tumor cell lines.
Among diethyltin(IV) complexes (3–5), complex 5 containing dptp
as ligand, showed an overall anti-proliferative efﬁcacy comparable
to cisplatin, while 3 and 4, containing dbtp in 1:1 and 1:2 M ratio,
respectively, were signiﬁcantly less active. However, experiments
performed to assay the activity of dbtp and dptp ligands used to
synthesize the organotin(IV) complexes, demonstrated that these
ligands were unable to exert any inhibitory activity (not shown).
Among the nine organotin(IV) complexes checked, only compound
6–9 exhibit a strong activity against HepG2, MCF-7 and HeLa, being
even more active than cisplatin, which is clinically widely used.
Under the same assay conditions, compounds 6–9, did not substan-
tially impaired the normal immortalized human Chang liver cells
viability (Fig. 4). Only a modest effect (15%) was observed after
treatment with 6 and 7 at 10 lM, suggesting tumor cells as the
main target of their cytocidal action.
On the basis of the data analysis, in agreement with what had
been observed in previous studies [29], possible structure–activity
relationships indicates that the biological activity of organotin(IV)
series depended on both the ligand and the R groups bound to tin
atom. Organo-R-groups appear to play an important role: indeed,
the di-n-butyltin complexes 6 and 7, exhibit the strongest antitu-
mor activity, while the diorganotin derivatives with a short
(methyl, ethyl) carbon chain exhibit very low activities. The activ-
ity of diphenyltin(IV) 8 and 9, on the other hand, is lower comparedcomplexes 6–9 induced apoptosis in HepG2. HepG2 cell monolayers were incubated
tted to double staining with Annexin V/PI as reported in Section 2. V3, viable cells
sis (AnnexinV+/PI+); V1, necrotic cells (AnnexinV/PI+). In red: mean ± SD (n = 3) of
comparable results.
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plexes, the activity follows the order nBu > Ph > Et > Me for the
tested tumor cells. Moreover, taking into account the ligands, cyto-
toxity results in Table 3 indicate that 7 and 9, containing dptp
ligands, exhibit better antitumor properties against HepG2 than 6
and 8 with dbpt ligands, as shown by their lower (0.6–3.0 lM)
IC50 values. On the other hand, 6 and 8 exhibit lower IC50 values
against MCF-7 and HeLa.
The tendency to obtain inhibitory activity as a function of
increasing lipophilicity in the series Me > Et > nBu > Ph, which facil-
itates cell membrane crossing, well agrees with the known rela-
tionship between organotin toxicity and hydrophobicity [30,31].
In the present study, an attempt was made to compare the anti-
tumor and antibacterial activity of the diorganotin(IV) complexes
substituted with different alkyl (methyl-, ethyl- and n-butyl) and
phenyl group. Our previous study [13] clearly indicated that 9
and 6 exhibit good antibacterial activity against Staphylococcus
aureus ATCC29213, with a MIC value of 5 and 10 lg mL1 respec-
tively, and compound 6 showed an interesting activity against
the methicillin resistant strain S. aureus ATCC43866 (MIC value of
20 lg mL1). The compounds 7–9, on the other hand, resulted
active against methicillin resistant Staphylococcus epidermidis
RP62A.
3.3. Apoptosis studies
Cell death can usually occurs by necrosis, inducing severe
inﬂammation, or by apoptosis. Apoptotic cells are transformed into
small membrane-bound vesicles (apoptotic bodies) which are
engulfed in vivo by macrophages, and no inﬂammatory response
is triggered. Therefore, induction of apoptosis is considered impor-
tant in the development of anticancer drugs and apoptotic markers
in cells treated with organotin(IV) complexes were investigated to
rationalize their inhibitory effects on cell viability. On the basis of
their cytotoxic effect, the most active complexes 6–9 were chosen
and their concentration selected on the basis that it represented
IC50 value at 24 h. Analysis was carried out on HepG2 cell line
against which the complexes 6–9 showed higher cytotoxicity than
cisplatinum. In the earlier events of the apoptotic process,Fig. 6. Fluorescence micrographs of ethidium bromide/acridine orange double stained He
individual complexes and submitted to double staining with AO/EB as reported in Sect
Representative images of three experiments with comparable results (200x magniﬁcatioscrambling of plasma membrane causes PS translocation from
the inner to the outer membrane [32]. Thus, PS is exposed to the
external environment and can bind to the annexin V-FITC conju-
gate, for which PS has a high afﬁnity [33]. On the latest stages of
the apoptotic process, as well as in necrotic processes, cell mem-
branes lose their integrity, allowing PI to access the nucleus and
intercalate between the DNA bases. FACS analysis using annexin
V-FITC/PI double staining, allows to differentiate viable cells
(annexin V and PI) from early (annexin V+ and PI) or late
apoptotic (annexin V+ and PI+) and necrotic (annexin V and
PI+) cells. As shown in Fig. 5 none of the complexes exerted necro-
tic effects on HepG2 cells, while inducing a clear pro-apoptotic
effect with cells distributed between early and late apoptosis.
Morphological evidence of apoptosis was obtained by a staining
method utilizing AO and EB which allows the identiﬁcation of via-
ble, apoptotic, and necrotic cells based on color and appearance.
Under the ﬂuorescence microscope, live cells appear green with
intact nuclei whereas necrotic cells, showing a nuclear morphology
resembling that of viable cells, stain red. Apoptosis is demon-
strated by the appearance of cell shrinkage with condensation
and breaking up of the nuclei. Apoptotic cells were easily distin-
guished from necrotic cells because the latter appeared orange
with a normal nuclear structure. As shown in Fig. 6, non-treated
living HepG2 cells (control) appeared uniformly green indicating
integrated structure and normal size. After 24 h exposition to the
complexes 6–9, cells in early apoptotis were observed, containing
bright green patches in the nuclei as a consequence of chromatin
condensation and nuclear fragmentation. Moreover, ﬂuorescing
orange cells, presenting cell shrinkage, chromatin condensation,
nuclear fragmentation, and formation of apoptotic bodies were
also evident as cells in late apoptosis (Fig. 6).
3.4. Cell cycle distribution analysis by ﬂow cytometry
The effects of the complexes 6–9 on HepG2 cell cycle distribu-
tion was determined by ﬂow cytometric analysis after staining of
DNA with PI. Differentiation between phases of the cell cycle is
based on the content of genetic material, which in non-dividing
cells is limited to one copy of DNA. The cell population in the SpG2 cells. Cells were incubated for 24 h in the absence (control) or in the presence of
ion 2. Cells in a–c are living, early apoptotic and late apoptotic cells, respectively.
n).
Fig. 7. Effect of complexes 6–9 on the cell cycle distribution of HepG2 cells. Flow cytometric analysis of propidium iodide-stained cells after 24 h treatment with the
compounds. The percentage of cells in the different phases of the cycle was calculated by Expo32 software. In red: percentage of viable cells in the different phases. In red:
mean ± SD (n = 3) of percentage of viable cells in the different phases. Representative images of three experiments with comparable results. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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thus contains more DNA than quiescent cells. The subsequent
G2/M phase (interphase/mitosis) is characterized by the presence
of two copies of DNA. At last, cells in the subdiploid region is con-
sidered as an index of apoptosis. Therefore, the alterations in these
phases are used as a basis for comparing different treatments.
As shown in Fig. 7, the complexes 6–9 caused an accumulation
of treated cells in subG0/G1 phase, conﬁrming their cytotoxic
effects, and induced a marked cell arrest in G0–G1 phase of the
cycle (more than 60%). These ﬁndings may suggest that these
complexes can affect the cell mechanisms promoting DNA
duplication.
4. Conclusions
The compounds 1–9were screened in vitro against three human
cancer cell lines, HepG2 (human hepatocellular carcinoma), HeLa
(human cervix adenocarcinoma) and MCF-7 (human breast cancer)
and with the normal immortalized human Chang liver cells as a
selectivity control. The nature (alkyl/phenyl) and size of covalently
attached R groups of Sn(IV) atom played a key role in the toxicities
of the reported complexes. Di-n-butyltin- and diphenyltin deriva-
tives 6–9 showed cell growth-inhibitory potencies, expressed as
IC50 values, much higher than cisplatin, the most clinically estab-
lished chemotherapeutic drug. The cell death mechanism exerted
by the organotin(IV) derivatives was apoptosis, as established in
HepG2 cells by ﬂow cytometric analysis of externalization of
plasma membrane phosphatidylserine externalization and ﬂuores-
cence microscopy after double staining with AO and EB. According
to results from cytoﬂuorimetric analysis of PI-stained cells, com-
plexes 6–9 appeared to inhibit cell entry in S-phase, thus inducing
cell death. Future studies will focus on the molecular mechanisms
by which organotin(IV) complexes induce cell cycle arrest.The molecular structure of the compounds 4 and 9 was previ-
ously investigated [13] and in the present study X-ray diffraction
data of compound 7 are reported. The results obtained conﬁrm
the importance of both conformational ﬂexibility in molecules
provided with biological activity, because typical drug molecules
represent a conﬂuence of conformational mobility and functional
complexity, and chirality in hitting the biological target. The lower
IC50 values exhibited by compounds 7 and 6, compared to the other
tested compounds, seem to suggest the singularity of the features
possessed among the other complexes investigated, of which, apart
from 4 and 9, unfortunately no solid state structure is available for
comparison.
In conclusion, it has been recently established that the
[R2Sn(IV)]2+ compounds with maximum antitumor activity
combined with low mammalian toxicity are adducts of the type
R2SnX2L2 (X = halogen, pseudohalogen, L = O- or N-donor ligand).
A large number of compounds have now been screened against a
variety of tumor cell lines, and several reviews have been
published as shown above. Structural features of diorganotin(IV)
complexes containing an N-donor atom, particularly longer Sn–N
bond length, could apparently favour binding to DNA, whereas
the inactive complexes had Sn–N bonds shorter than 2.39 Å, at
least for bidentate N ligands. The Sn-N bond length in the highly
active complex 7, well beyond the ‘‘threshold’’ for activity, can be
compared to the results obtained from the investigations of the
crystal structures of compounds 4 and 9. Actually, while 4 shows
only a modest anti-proliferative activity in vitro, 9 behaves much
better than cisplatin, showing also selectivity towards tumor cells.
In our opinion, reasons for determining activity or inactivity of
organotin(IV) compounds with monodentate N-donor are much
more the result of an interplay of favorable steric, enantiomeric
and conformational factors summed up to the nature of the
organotin(IV) ligands than the single geometric parameters.
176 M.A. Girasolo et al. / Inorganica Chimica Acta 423 (2014) 168–176Hopefully, further structural studies will cast some light on elu-
cidation of their mechanism of action.
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